June 13, 2025
New shock to investors; external influences damage sector after econs reaps their harm
News: Moderna (MRNA -$0.70 or -2.56% to $27.35) the U.S. FDA has approved mRESVIA® (mRNA-1345), its respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease. This approval expands the previous indication of mRESVIA, which was approved in May 2024 for adults aged 60 years and older.
Headed south: (ALNY -$4.16), (BEAM -$0.24), (CRSP -$1.63), (LENZ -$0.78), (AXGN -$0.11) – just a few, many with no indication pre-open
No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief
Never leave an investor uninformed!
June 12, 2025
Newest ...
6/10/25 ... OTCQB: HRGN drops -$0.17 to $1.51 on 12 shares traded ... guess I have been right all along!!
6/4/25 ... OTCQB: HRGN... Questions exist as stock dives in afternoon -$0.7141 to $0.93 with 5000 shares traded and suddenly is “resurrected” at the close to +$0.01 with 9,250 shares traded – PONZI Scheme at its best or was convicted Bernie Madoff also resurrected in DST Capital (run by HRGN’s President)???
No partner, No cash, NO runway, extensive liabilities and debts to past employee and university associations
June 13, 2025
RMi provides the insight to viable pricing, and discovering which sector companies are trading or atrophying before and after the broader market catches flak with the VIX rising to 20.82
News: Moderna's (MRNA -$0.68 or -2.49% to $26.67) fell on concerns about whether a new CDC advisory panel (after Health Secretary Robert F. Kennedy Jr. replaced all 17 members of a key panel this week, with some of the new appointees having openly expressed anti-vaccine views) would back the use of its respiratory syncytial virus vaccine in a broader age group. While shares of Glaxo (GSK -$1.63 or -3.84% to $40.86) which markets rival RSV shot Arexvy fell and Pfizer (PFE -$0.30 or -1.21% to $24.54), which sells RSV shot Abrysvo, also fell although marginally. BioNTech (BNTX +$1.65 or +1.57% $106.57) agreed to acquire mRNA specialist CureVac for approximately $1.25bn, amping-up its strategy to offer cancer treatments; CureVac (CVAC -$0.03 -$0.54 to $5.57) in an all-stock transaction
Beam Therapeutics (BEAM -$0.38 or -2.18% to $17.06) new safety and efficacy data from its BEACON P1/2 clinical trial of BEAM-101 in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs). Updated data from 17 patients treated with BEAM-101 demonstrated robust and durable increases in fetal hemoglobin (HbF) and reductions in sickle hemoglobin (HbS), rapid neutrophil and platelet engraftment, and normalized or improved markers of hemolysis and oxygen delivery.
TGIF
Never leave an investor uninformed!
June 12, 2025
Newest ... 6/10/25 ... OTCQB: HRGN drops -$0.17 to $1.51 on 12 shares traded ... guess I have been right all along!! 6/4/25 ... OTCQB: HRGN... Questions exist as stock dives in afternoon -$0.7141 to $0.93 with 5000 shares traded and suddenly is “resurrected” at the close to +$0.01 with 9,250 shares traded – PONZI Scheme at its best or was convicted Bernie Madoff also resurrected in DST Capital (run by HRGN’s President)??? No partner, No cash, NO runway, extensive liabilities and debts to past employee and university associations Harvard Apparatus RT (OTCQB: HRGN) Net loss of -$1.659 M or -$0.10 per share, revenue of $45 K, cash position of $1.728 M with a Q2/25 runway; accumulated deficit of -$101.3 M, liabilities of -$11.9 K in addition to -$207 K owed to former employees, and 161 K to Un of Pitt and Yale <No release, 8-K, filed 5/14>. What about past (still unpaid for months of work) consultants with documentation!! Going Concern status still in effect.
May 13, 2025
SGMO is trading at $0.449 down -$0.2967 or -39.7% Cantor is acting as sole book-running manager for the offering.
March 10, 2025
including pre-funded warrants to purchase 1,404,988 shares of common stock at an offering price of $28.47 per pre-funded warrant with an exercise price of $0.01 per share. BEAM closed Friday at $1.23 to $28.48 with a pre-open indication of $2.57 or +0.02% to $31.05 Gross proceeds from the offering are expected to be approximately $500.0 million expected to close on or about 3/11/2525
2 hours 14 min ago
RegMed Investors (RMi) Closing Bell: sector bottoms evident as collateral damage
12 hours 28 min ago
RegMed Investors’ (RMi) pre-open: Bombs away
12 hours 28 min ago
RegMed Investors’ (RMi) pre-open: Bombs away
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
